These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 9465321)

  • 21. [Acute myeloic leukemia: evaluation of colony-stimulating factors].
    Hiddemann W
    Dtsch Med Wochenschr; 2012 Nov; 137(45):2306. PubMed ID: 23111791
    [No Abstract]   [Full Text] [Related]  

  • 22. [Indications for the use of granulocyte growth factors].
    Elonen E
    Duodecim; 1997; 113(22):2319-25. PubMed ID: 10892137
    [No Abstract]   [Full Text] [Related]  

  • 23. Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy?
    Touw IP; Bontenbal M
    J Natl Cancer Inst; 2007 Feb; 99(3):183-6. PubMed ID: 17284707
    [No Abstract]   [Full Text] [Related]  

  • 24. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.
    Johnston EM; Crawford J
    Semin Oncol; 1998 Oct; 25(5):552-61. PubMed ID: 9783594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematopoietic growth factors--use in normal blood and stem cell donors: clinical and ethical issues.
    McCullough J; Kahn J; Adamson J; Anderlini P; Benjamin R; Confer D; Eapen M; Hirsch B; Kuter D; Lazarus E; Pamphilon D; Stroncek D; Sugarman J; Wilson R
    Transfusion; 2008 Sep; 48(9):2008-25. PubMed ID: 18564401
    [No Abstract]   [Full Text] [Related]  

  • 26. Should hematopoietic growth factors routinely be given concurrently with cytotoxic chemotherapy?
    Croockewit AJ; Koopmans PP; de Pauw BE
    Clin Pharmacol Ther; 1996 Jan; 59(1):1-6. PubMed ID: 8549028
    [No Abstract]   [Full Text] [Related]  

  • 27. [Rational therapy with G-CSF and GM-CSF].
    Link H; Herrmann F; Welte K; Aulitzky WE; Ganser A; Kern WV; Meyer P; Schrappe M; Schmoll HJ; Werdan K
    Med Klin (Munich); 1994 Aug; 89(8):429-41. PubMed ID: 7526144
    [No Abstract]   [Full Text] [Related]  

  • 28. [The dilemma of stimulating factors in the recovery from chemotherapeutic neutropenia].
    Borbollo Escoboza JR; González Avante M; Alvarado Ibarra M
    Rev Invest Clin; 1996; 48(4):328. PubMed ID: 8966397
    [No Abstract]   [Full Text] [Related]  

  • 29. Towards improved cancer therapy using subcutaneously administered hemopoietic colony stimulating factors.
    Morstyn G; Sheridan W; Lieschke G; Cebon J; Layton J; Fox R
    Prog Clin Biol Res; 1990; 354B():29-36. PubMed ID: 1700441
    [No Abstract]   [Full Text] [Related]  

  • 30. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
    Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
    Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia.
    Freyer G; Ligneau B; Trillet-Lenoir V
    Int J Antimicrob Agents; 1998 Apr; 10(1):3-9. PubMed ID: 9624538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Recommendation for using granulocyte and granulocyte-macrophage growth factor during anti-cancer therapy in children].
    Balwierz W; Moryl-Bujakowska A; Balwierz A; Pawińska K
    Przegl Lek; 2006; 63(1):1-6. PubMed ID: 16892890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematopoietic colony-stimulating factors and dose intensity.
    Petros WP; Peters WP
    Semin Oncol; 1993 Feb; 20(1):94-9. PubMed ID: 7682727
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte-macrophage colony-stimulating factor in neutropenic children with malignancies.
    Lydaki E; Bolonaki E; Stiakaki E; Dimitriou H; Kalmantis T; Kalmanti M
    Pediatr Hematol Oncol; 1995; 12(6):551-8. PubMed ID: 8589000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia.
    Klastersky J; Raftopoulos H; Rapoport B
    Support Care Cancer; 2013 Jun; 21(6):1793-5. PubMed ID: 23525960
    [No Abstract]   [Full Text] [Related]  

  • 36. [Myeloid growth factors can cure chronic neutropenia and facilitate cytostatic therapy].
    Palmblad J; Samuelsson J
    Lakartidningen; 1992 Mar; 89(13):1037-8, 1041. PubMed ID: 1372671
    [No Abstract]   [Full Text] [Related]  

  • 37. Haemopoietic growth factors for neonates: assessing risks and benefits.
    Carr R; Modi N
    Acta Paediatr Suppl; 2004 Feb; 93(444):15-9. PubMed ID: 15035456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia.
    Schiffer CA
    Blood; 1996 Nov; 88(10):3675-85. PubMed ID: 8916931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
    Weycker D; Barron RL
    Cancer; 2010 Jun; 116(12):3073; author reply 3073-4. PubMed ID: 20564415
    [No Abstract]   [Full Text] [Related]  

  • 40. The role of myelopoietic growth factors in managing cancer in the elderly.
    Balducci L; Carreca I
    Drugs; 2002; 62 Suppl 1():47-63. PubMed ID: 12479594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.